EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)
The long-awaited decision by the European committee CHMP was announced recently by Amylyx Pharmaceutical (the Company) based in Cambridge, Massachusetts just as anticipated. The EMA issued its negative opinion of…